MMR: patient group direction (PGD) template
PGD template to support the national MMR vaccination programme.
- From:
- UK Health Security Agency
- Published
- 24 March 2016
- Last updated
-
3027JanuaryNovember20242025 — See all updates
Applies to England
Documents
MMR: patient group direction (PGD) template
Ref: UKHSA gateway number: GOV-15882
MS Word Document, 176258 KB
This file may not be suitable for users of assistive technology.
Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@ukhsa.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.
Details
This patient group direction (PGD) template supports the administration of measles, mumps and rubella (MMR) vaccine, to individuals from 1 year of age for routine immunisation or from 6 months of age if early protection is required, in accordance with the national immunisation programme and the UK Health Security Agency (UKHSA) guidelines on post-exposure prophylaxis for measles.
MMR vaccine PGD version 5.006.0 is valid from 291 FebruaryJanuary 20242026 to 3130 JanuaryNovember 2027.2028.
Practitioners must not use this PGD template until it has been authorised in Section 2. This is a legal requirement (see Human Medicines Regulations 2012). Practitioners should follow local policy and procedures to access authorised PGD documents.
This PGD template should be used with reference to current national guidance, the Green Book, and Summary of Product Characteristics for the vaccine.
Updates to this page
Published 24 March 2016
Last updated 3027 JanuaryNovember 2024
+ show2025
href="#full-history">+ show all updates
-
Sign up for emails or print this page
MMR: patient group direction (PGD) template
Ref: UKHSA gateway number: GOV-15882
MS Word Document, 176258 KB
This file may not be suitable for users of assistive technology.
Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@ukhsa.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.
Details
This patient group direction (PGD) template supports the administration of measles, mumps and rubella (MMR) vaccine, to individuals from 1 year of age for routine immunisation or from 6 months of age if early protection is required, in accordance with the national immunisation programme and the UK Health Security Agency (UKHSA) guidelines on post-exposure prophylaxis for measles.
MMR vaccine PGD version 5.006.0 is valid from 291 FebruaryJanuary 20242026 to 3130 JanuaryNovember 2027.2028.
Practitioners must not use this PGD template until it has been authorised in Section 2. This is a legal requirement (see Human Medicines Regulations 2012). Practitioners should follow local policy and procedures to access authorised PGD documents.
This PGD template should be used with reference to current national guidance, the Green Book, and Summary of Product Characteristics for the vaccine.
Updates to this page
Published 24 March 2016
Last updated 3027 JanuaryNovember 2024
+ show2025
href="#full-history">+ show all updates
-
Sign up for emails or print this page
Details
This patient group direction (PGD) template supports the administration of measles, mumps and rubella (MMR) vaccine, to individuals from 1 year of age for routine immunisation or from 6 months of age if early protection is required, in accordance with the national immunisation programme and the UK Health Security Agency (UKHSA) guidelines on post-exposure prophylaxis for measles.
MMR vaccine PGD version 5.006.0 is valid from 291 FebruaryJanuary 20242026 to 3130 JanuaryNovember 2027.2028.
Practitioners must not use this PGD template until it has been authorised in Section 2. This is a legal requirement (see Human Medicines Regulations 2012). Practitioners should follow local policy and procedures to access authorised PGD documents.
This PGD template should be used with reference to current national guidance, the Green Book, and Summary of Product Characteristics for the vaccine.